Anavex Life Sciences Corp (OTCBB: AVXL) will move to human clinical trials for its Alzheimer’s drug in early 2009 after preclinical studies on mice prove promising.

Investing in biotech stocks can be incredibly rewarding, financially and personally, says Marc Lichtenfeld writing in Investment U. However, timing is crucial to success. Here, Marc walks investors through the three phases of the drug development process…

Streamline Health Solutions, Inc. (STRM.OB), a leading supplier of workflow and document management tools, applications and services that assist strategic business partners and healthcare organizations to improve operational efficiencies, recently announced the company’s financial results for the second quarter of fiscal year 2008 ended July 31, 2008.

For shareholders of Pfizer, Inc. (PFE) stock, it has been a pretty barren decade. No investor can look at Pfizer’s ten year chart and miss the fact that the stock has been a multi-year dog. However, from a valuation standpoint, these high-yielding shares are worthy of consideration for patient, income-oriented investors.

The smiles are bigger around the offices of Remedent and Den-Mat Holdings this week. The two companies signed an international distribution and collaboration agreement Monday for new cosmetic dentistry products. Den-Mat has acquired exclusive rights to domestically and internationally manufacture, market and distribute GlamSmile technology to enhance its own porcelain Lumineers line.

Dyax Corp. (Nasdaq: DYAX) is a clinical-stage drug company focused on the discovery, development and commercialization of biotherapeutics for oncology and inflammatory conditions.

Shares of Zynex Inc. (OTCBB: ZYXI) climbed 17% to $6 Friday afternoon after the company reported its second quarter financial results for 2008, posting triple-digit increases for the period ended June 30, 2008.

But by keeping interest rates below the rate of inflation for three straight years starting in 2002, the Fed created a bubble in the housing market. That bubble has now popped, leaving in its wake a severe liquidity crisis.

China Medicine Corporation (CHME.OB), a developer and distributor of pharmaceuticals and nutritional supplements in China, reported strong second quarter financial results this morning. Revenues increased 40.8% year over year to $11.6 million, compared to $8.3 million in Q2 2007. Net income soared 118.8% to $2.5 million, or 16 cents per share, vs. $1.1 million, or 8 cents per share a year ago.

Popular conceptions of value-investing are debatable. How can you be sanguine that future projections about any stock are reliable? Here is a small-capital example from Bethesda, MD that you can use. It demonstrates the powers of adaptability and innovation in building the best platforms for business.

EXACT Sciences Corporation (NASDAQ: EXAS), a research and development company focused on developing non-invasive screening technologies for early detection of colorectal cancer, recently announced published results of a comprehensive colorectal cancer detection study in which stool and blood plasma were individually assessed to determine which type of testing was more accurate in detecting the dis

There has been a lot of strong recommendations around biotech lately on Contrarian Profits. Phase 1 Investor editor Rob Fannon recently wrote that biotech was one of the few market sectors to show positive returns as many other stocks were getting hammered. He sees great values in the sector.

AtheroGenics Inc. (Nasdaq: AGIX) is a pharmaceutical company focused on the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease. The company today announced top-line results from its ANDES phase 3 clinical trial of AGI-1067, the company’s lead antioxidant and anti-inflammatory drug candidate for the treatment of type 2 diabetes.

Bio-Imaging Technologies, Inc. (BITI) is a contract healthcare service organization that provides support to the pharmaceutical, biotechnology and medical device industries during clinical trial processes. Bio-Imaging reported second quarter results this morning that surpassed analysts’ estimates.

If the deal does go through it may be bad news for Roche and Genentech shareholders, according to Phase 1 Investor editor Rob Fannon in The Growth Stock Wire. But it would be good news for the biotech industry as a whole…